Table 2.
Immunological status of children during intervention period #.
| Placebo | Supplement | |||
|---|---|---|---|---|
| Follow Up | n | CD4 Percentage | n | CD4 Percentage |
| Enrolment | 63 | 24.7 (21.6 to 27.9) | 57 | 23.9 (20.5 to 27.3) |
| 3 mo | 48 | 27.1 (23.3 to 30.9) | 41 | 23.9 (19.8 to 27.9) |
| 6 mo | 42 | 28.0 (24.2 to 31.7) | 35 | 25.3 (20.8 to 29.9) |
| Δ3mo | 48 | −0.83 (−2.68 to 1.02) | 41 | −2.06 (−4.33 to 0.01) |
| Δ 6 mo | 42 | −1.44 (−3.71 to 0.83) | 35 | −0.64 (−3.39 to 2.11) |
Values presented as mean (95% CI); # There were no significant differences between the two treatment groups in both absolute values and changes over 3 and 6 months.